Results 121 to 130 of about 10,425 (248)

Characteristics of deaths due to drug‐related causes among individuals recently released from prison in the United Kingdom, 1997–2025

Addiction, EarlyView.
Abstract Background and aims There has been an extensive literature describing the elevated risk of drug‐related death following an individual's release from prison; however, few previous studies have reported nationally representative samples or provided granular detail as to which individual drugs were deemed implicated in death.
Emmert Roberts, John Strang, Caroline Copeland   +2 more
wiley   +1 more source

Efficient propagation protocol and genetic similarity assessment of medicinal cannabis based on photoautotrophic micropropagation. [PDF]

Front Plant Sci
Liang J, Wei X, Liu J, Zhou Q, He D.
europepmc   +1 more source

Holistic approach to substance‐induced psychosis

Addiction, EarlyView.
Julia M. Lappin, Shane Darke, Michael Farrell   +2 more
wiley   +1 more source

Change of substance‐related hospitalisation in adolescents after cannabis legalisation in Thailand in 2022

Addiction, EarlyView.
Abstract Background and aims On 9 June 2022, Thailand changed its cannabis legislation, expanding access to individuals aged >18 years. Evidence suggests that such changes could increase the risk of cannabis use and related harms, and could influence patterns of use of other substances among adolescents.
Sirada Puetpaiboon, Songyos Rajborirug, Vorthunju Nakhonsri, Chumpol Ngamphiw, Peerapat Khunkham, Sissades Tongsima, Watcharapot Janpoung, Virasakdi Chongsuvivatwong   +7 more
wiley   +1 more source

Higher THC Concentration Medicinal Cannabis Products Efficacy and Safety Considerations: A Rapid Review. [PDF]

Drug Alcohol Rev
Graham M, Assefa D, Cong-Lem N, Nielsen S.   +3 more
europepmc   +1 more source

Brain reward function in young people with cannabis use disorder: A functional magnetic resonance imaging study

Addiction, EarlyView.
Abstract Background and Aims Cannabis use disorder (CUD) affects ~50 million people globally. Neuroscientific theories suggest that a blunted neural response to non‐drug rewards is a hallmark of substance use disorders; however, this remains untested in CUD. The current study tested whether brain reward system responses to the anticipation and feedback
Martine Skumlien, Lisa‐Marie Greenwood, Arush Honnedevasthana Arun, Isabella Goodwin, Anastasia Paloubis, Tribikram Thapa Rana, Marianna Quinones Valera, Eugene McTavish, Gabrielle Abbott, Suraya Dunsford, Antonio Verdejo‐Garcia, Jessica Ramamurthy, Mark M. Schira, Nadia Solowij, Chao Suo, Valentina Lorenzetti   +15 more
wiley   +1 more source

A retrospective analysis of voluntary adverse event reports to the TGA with higher THC medicinal cannabis products. [PDF]

Aust N Z J Psychiatry
Graham M, Tisdale C, Nielsen S.
europepmc   +1 more source

Collaborative care intervention for risky opioid use among primary care patients: The STOP randomized clinical trial

Addiction, EarlyView.
Abstract Background and aims Individuals who engage in illicit or nonmedical opioid use may have elevated risk of health and social consequences, including progression to opioid use disorder (OUD). Preventive interventions to reduce this risk are lacking. This trial tested the impact of a primary care‐integrated collaborative care approach for reducing
Jennifer McNeely, Geetha A. Subramaniam, Rebecca Stone, Shayna Mazel, Noa Appleton, Yasna Rostam‐Abadi, Amanda M. Bunting, Yidan Shi, Travis I. Lovejoy, Lillian Gelberg, Donna Beers, Margaret Kline, Song Zhang, Tobie Kim, Ashley Case, Jennifer McCormack, Michael A. Incze, Jane M. Liebschutz, the STOP trial site principal investigators, Karen Alexander, Seuli Bose Brill, Sarah Kawasaki, Adam J. Gordon, Hyunouk Hong   +23 more
wiley   +1 more source

Prevalence and risk perceptions of nicotine pouch use: A systematic review of population‐based studies

Addiction, EarlyView.
Abstract Background and Aims Oral nicotine pouches (NPs) are a new class of non‐combustible nicotine products that have gained rapid popularity. Despite rising sales and marketing, evidence of their prevalence and risk perceptions remains limited. This systematic review aimed to synthesize the available global evidence on the prevalence and patterns of
Salma Mahmoodianfard, Spencer Shahen, Javad Heshmati, Emma Bates, Evyanne Quirouette, Terefe Gelibo, Sarah Visintini, Hassan Mir   +7 more
wiley   +1 more source

Nanotechnology for the Efficacious Delivery of Medicinal Cannabis and Pharmaceutical Medicines. [PDF]

Pharmaceuticals (Basel)
Vitetta L, Henson JD, Hayes E, Rutolo D, Hall S.   +4 more
europepmc   +1 more source